Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14211892 | 0.95 | CNR1 (0.91) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL14211170 | 0.93 | CNR1 (0.86) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL14181070 | 0.92 | CNR1 (0.85) | CNR1CYP2C9CYP2C19CYP3A4NPC1 | |
| SCHEMBL14181112 | 0.92 | CNR1 (0.85) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL14211173 | 0.92 | CNR1 (0.85) | CNR1CYP2C9CYP2C19CYP3A4NPC1 | |
| SCHEMBL14212434 | 0.92 | CNR1 (0.85) | CNR1CYP2C9CYP2C19CYP3A4NPC1 | |
| SCHEMBL14211180 | 0.91 | CNR1 (0.84) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL14212433 | 0.91 | CNR1 (0.84) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL14212187 | 0.91 | CNR1 (0.84) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL14210241 | 0.91 | CNR1 (0.84) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1697370-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1697370-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1697370-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063761-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050143381-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BROSTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143381-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, CCKBR | CNR1 1/4885CYP2C9 415/4885CYP2C19 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.